Co‑injecting three common amino acids with LNPs dramatically boosted both mRNA delivery and CRISPR gene editing efficiency in ...
CRISPR Therapeutics received marketing approval from the U.S. Food and Drug Administration for its first drug, called Casgevy, on Dec. 8. Shares of CRISPR Therapeutics fell sharply in response to what ...
Current shareholders were thrown an unexpected curveball that they actually should have been expecting.
Now, it’s worth noting Stock Advisor’s total average return is 892 % — a market-crushing outperformance compared to 194% for ...
Following the recent FDA green light for the gene therapy Casgevy, "it is unlikely" that approval of a similar product will take place "any time soon," according to a report by GlobalData. According ...
Rapid advancements in CRISPR and next-generation gene editing technologies, combined with a strong clinical pipeline ...
Last week, in a global milestone for medicine, U.K. regulators approved the first-ever CRISPR gene-editing drug. The treatment, from Vertex and CRISPR Therapeutics, will be licensed under the brand ...
In a landmark announcement for the CRISPR field and the sickle cell disease (SCD) community, the U.K. authorities have granted approval to Casgevy, the CRISPR-Cas9 therapy formerly known as exa-cel ...
Scientists used CRISPR tech to create a custom-made drug targeted at helping a newborn baby fight a rare genetic disorder. According to an extraordinary new paper published in The New England Journal ...
To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Preview this article 1 min In a first for the Nobel Prize ...
Gene editing pioneer CRISPR Therapeutics (NASDAQ: CRSP) passed a major milestone on Dec. 8. The U.S. Food and Drug Administration (FDA) approved its first therapy, Casgevy, to treat patients with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results